Through qRT-PCR analysis, we confirmed reduced SMAD6 variant 2 mRNA expressions in all examined tumors, indicating HCC-specific down-regulation of variant 2 (Fig. 3b). This evidence concerns the gene SMAD6 and hepatocellular carcinoma.